Acumen Pharmaceuticals, Inc.
ABOS
$2.26
-$0.03-1.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 90.06% | 102.96% | 122.67% | 90.70% | 113.87% |
| Gross Profit | -90.06% | -102.96% | -122.67% | -90.70% | -113.87% |
| SG&A Expenses | -4.60% | -4.15% | -3.18% | 3.25% | 11.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.24% | 70.87% | 114.20% | 101.17% | 80.89% |
| Operating Income | -71.24% | -70.87% | -114.20% | -101.17% | -80.89% |
| Income Before Tax | -99.40% | -93.61% | -125.22% | -129.72% | -76.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.40% | -93.61% | -125.22% | -129.72% | -76.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.40% | -93.61% | -125.22% | -129.72% | -76.89% |
| EBIT | -71.24% | -70.87% | -114.20% | -101.17% | -80.89% |
| EBITDA | -71.29% | -70.94% | -114.34% | -101.23% | -80.97% |
| EPS Basic | -97.78% | -91.31% | -117.44% | -107.37% | -20.78% |
| Normalized Basic EPS | -97.80% | -91.38% | -117.50% | -107.37% | -20.75% |
| EPS Diluted | -97.78% | -91.31% | -117.44% | -107.37% | -20.78% |
| Normalized Diluted EPS | -97.80% | -91.38% | -117.50% | -107.37% | -20.75% |
| Average Basic Shares Outstanding | 0.82% | 1.19% | 3.56% | 10.79% | 46.45% |
| Average Diluted Shares Outstanding | 0.82% | 1.19% | 3.56% | 10.79% | 46.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |